Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874848 · ClinicalTrials.gov registry record · Phase 2
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by HiberCell.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00874848 is a Phase 2 study that has completed, run by HiberCell. The registered enrollment target is 90 participants.
The verdict
NCT00874848, a Phase 2 study, has completed, sponsored by HiberCell.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Interventions
- DRUG Carboplatin
- BIOLOGICAL Cetuximab
- DRUG Paclitaxel
- BIOLOGICAL Imprime PGG Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874848
The ClinicalTrials.gov registry entry for NCT00874848 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HiberCell, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00874848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00874848 about?
NCT00874848 is a clinical study titled "Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer". The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study...
What is the current status of trial NCT00874848?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2009-08. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00874848?
The interventions under investigation include: Carboplatin (DRUG), Cetuximab (BIOLOGICAL), Paclitaxel (DRUG), Imprime PGG Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00874848?
This trial is sponsored by HiberCell, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.